Related references
Note: Only part of the references are listed.Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
Crenolanib is a selective type I pan-FLT3 inhibitor
Catherine Choy Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Joseph Schlessinger
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
FLT3 Inhibitors in AML: Are We There Yet?
Akshay Sudhindra et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2014)
Kinase Drug Discovery - What's Next in the Field?
Philip Cohen et al.
ACS CHEMICAL BIOLOGY (2013)
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Sander Pronk et al.
BIOINFORMATICS (2013)
Transient Exposure to Quizartinib Mediates Sustained Inhibition of FLT3 Signaling while Specifically Inducing Apoptosis in FLT3-Activated Leukemia Cells
Ruwanthi N. Gunawardane et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
C. Albers et al.
LEUKEMIA (2013)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
Michele McTigue et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Protein kinase biochemistry and drug discovery
Phillip A. Schwartz et al.
BIOORGANIC CHEMISTRY (2011)
Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex
Kenneth Verstraete et al.
BLOOD (2011)
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Paul D. Adams et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Characterizing the Effects of the Juxtamembrane Domain on Vascular Endothelial Growth Factor Receptor-2 Enzymatic Activity, Autophosphorylation, and Inhibition by Axitinib
James Solowiej et al.
BIOCHEMISTRY (2009)
Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors
Hitesh K. Patel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680
MA Young et al.
CANCER RESEARCH (2006)
FLT3 tyrosine kinase inhibitors
M Levis et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2005)
The structural basis for autoinhibition of FLT3 by the juxtamembrane domain
J Griffith et al.
MOLECULAR CELL (2004)
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase
CD Mol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Coot:: model-building tools for molecular graphics
P Emsley et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)
Juxtamembrane autoinhibition in receptor tyrosine kinases
SR Hubbard
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Structure of a c-Kit product complex reveals the basis for kinase transactivation
CD Mol et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The conformational plasticity of protein kinases
M Huse et al.
CELL (2002)
Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region
LE Wybenga-Groot et al.
CELL (2001)
Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
T Schindler et al.
SCIENCE (2000)
The activation loop in Lck regulates oncogenic potential by inhibiting basal kinase activity and restricting substrate specificity
LE Laham et al.
ONCOGENE (2000)
Share Paper
